Polycythemia Vera

Video Resources

Patient Stories

Hear from real patients taking Jakafi® (ruxolitinib). If you've already tried hydroxyurea to treat your PV and it didn’t work or you couldn’t tolerate it, you’re not alone.

Rob's Story

See how Rob, an avid gardener and keen outdoorsman, adjusted to life with polycythemia vera (PV) and how taking Jakafi helped move his PV journey forward.

IncyteCARES Patient Experiences

Hear how the patient support program, IncyteCARES, has helped eligible patients with information and support for the treatment journey with Jakafi.

Sue’s IncyteCARES Story

Hear Sue share how IncyteCARES—a patient support program for eligible adults taking Jakafi—connected her with information regarding coverage and educational support to help her throughout her journey with Jakafi.

Rob’s IncyteCARES Story

IncyteCARES gave Rob additional support to help move his treatment journey forward. Learn more about this patient support program for eligible adults taking Jakafi.

Dan’s IncyteCARES Story

IncyteCARES helped support Dan through his treatment journey with Jakafi. Find out how this patient support program for adults taking Jakafi has provided ongoing support when he needed it.

Professional Perspectives

Hear from a medical professional who specializes in myeloproliferative neoplasms such as PV. When it comes to learning about your condition, it can be helpful to listen to real myeloproliferative neoplasm (MPN) experts who treat these rare, chronic blood cancers every day. The following videos have been developed to help you learn more about your polycythemia vera and discover what may be possible with Jakafi.

Exploring a Targeted Therapy Called Jakafi

Discover how Jakafi works to reduce overactive JAK signaling.

What Effects Has Jakafi Shown in Clinical Trials?

Learn how targeted therapy with Jakafi affected patients’ hematocrit control, blood counts and spleen size after 8 months of treatment, when compared against other standard therapies.

How Do I Know if Hydroxyurea Is Not Right for Me?

Listen to an MPN expert discuss the challenges that patients with PV may experience when treated with a chemotherapy medicine called hydroxyurea.

How Do I Take Jakafi?

Find out how patients can work with their Healthcare Professional to ensure they are prescribed the dose of Jakafi that is appropriate for their particular circumstances.

Is Jakafi Long-Term Treatment?

Learn about the patients and conditions Jakafi is used to treat.

What Are the Common Side Effects of Jakafi?

Explore the most common side effects of Jakafi and learn what patients should report to their Healthcare Professional.

Educational Videos

Learn more about polycythemia vera with an educational video designed to support your treatment journey with Jakafi.

Polycythemia Vera, Spleen Size & You

Learn why spleen size is an important health focus in PV and how patients can partner with their Healthcare Professionals to help identify and monitor the signs and symptoms of spleen enlargement in PV.


Connect With
a Patient
Like Cam

Connect With a
Patient Like Cam

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering

Expand Collapse



Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.